QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.19%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-3.97%)
GE   106.07 (+-0.01%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:EQRX

EQRx (EQRX) Stock Forecast, Price & News

$1.79
-0.06 (-3.24%)
(As of 05:21 PM ET)
Compare
Today's Range
$1.76
$1.88
50-Day Range
$1.61
$1.96
52-Week Range
$1.58
$6.05
Volume
976,263 shs
Average Volume
2.42 million shs
Market Capitalization
$872.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.57

EQRx MarketRank™ Forecast

Analyst Rating
Hold
1.67 Rating Score
Upside/​Downside
155.1% Upside
$4.57 Price Target
Short Interest
Bearish
7.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.92mentions of EQRx in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.57) to ($0.66) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

564th out of 981 stocks

Pharmaceutical Preparations Industry

271st out of 479 stocks


EQRX stock logo

About EQRx (NASDAQ:EQRX) Stock

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Receive EQRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EQRx and its competitors with MarketBeat's FREE daily newsletter.

EQRX Stock News Headlines

EQRx (NASDAQ:EQRX) Stock Price Up 3.6%
EQRx (NASDAQ:EQRX) Trading Down 4.9%
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
The World Has Its Way With EQRx
Q1 2023 EQRx Inc Earnings Call
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
EQRx (EQRX) Scheduled to Post Quarterly Earnings on Monday
Earnings Outlook For EQRx
EQRx (NASDAQ:EQRX) Trading Down 4.8%
EQRx (NASDAQ:EQRX) Stock Price Down 3.3%
EQRx GAAP EPS of -$0.05 beats by $0.14
5 Best Affordable Stocks to Buy Under $5
See More Headlines

EQRX Price History

EQRX Company Calendar

Last Earnings
5/08/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EQRX
Fax
N/A
Employees
240
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.57
High Stock Price Forecast
$5.50
Low Stock Price Forecast
$3.20
Forecasted Upside/Downside
+155.1%
Consensus Rating
Hold
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$-169,090,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.90 per share

Miscellaneous

Free Float
398,172,000
Market Cap
$872.37 million
Optionable
Optionable
Beta
0.57

Key Executives

  • Mr. Alexis A. Borisy A.M. (Age 51)
    Founder & Exec. Chairman of Board of Directors
    Comp: $858.22k
  • Ms. Melanie I. Nallicheri (Age 54)
    CEO & Director
    Comp: $832k
  • Ms. Jamilu E. Rubin (Age 59)
    Chief Financial Officer
    Comp: $479.57k
  • Dr. Eric E. Hedrick M.D. (Age 58)
    Chief Physician Exec.
    Comp: $575.1k
  • Mr. Robert Forrester LL.B. (Age 59)
    Co-Founder & Advisor
  • Dr. Peter B. Bach M.D. (Age 58)
    MAPP, Co-Founder & Advisor
  • Sir Andrew Dillon CBE
    Co-Founder & Advisor
  • Mr. Daniel Hoey (Age 56)
    Chief of Technical Operations
  • Ms. Dina Ciarimboli J.D. (Age 54)
    Gen. Counsel & Corp. Sec.
  • Ms. Rona Anhalt (Age 58)
    Chief People Officer













EQRX Stock - Frequently Asked Questions

Should I buy or sell EQRx stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EQRx in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EQRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EQRX, but not buy additional shares or sell existing shares.
View EQRX analyst ratings
or view top-rated stocks.

What is EQRx's stock price forecast for 2023?

3 Wall Street analysts have issued 1 year target prices for EQRx's stock. Their EQRX share price forecasts range from $3.20 to $5.50. On average, they expect the company's share price to reach $4.57 in the next year. This suggests a possible upside of 155.1% from the stock's current price.
View analysts price targets for EQRX
or view top-rated stocks among Wall Street analysts.

How have EQRX shares performed in 2023?

EQRx's stock was trading at $2.46 on January 1st, 2023. Since then, EQRX stock has decreased by 27.2% and is now trading at $1.79.
View the best growth stocks for 2023 here
.

When is EQRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our EQRX earnings forecast
.

How were EQRx's earnings last quarter?

EQRx, Inc. (NASDAQ:EQRX) announced its earnings results on Monday, May, 8th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.05.

What is EQRx's stock symbol?

EQRx trades on the NASDAQ under the ticker symbol "EQRX."

Who are EQRx's major shareholders?

EQRx's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (5.05%), Softbank Group CORP. (4.44%), BlackRock Inc. (3.28%), State Street Corp (2.90%), Arboretum Ventures LLC (2.85%) and Geode Capital Management LLC (0.90%).

How do I buy shares of EQRx?

Shares of EQRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is EQRx's stock price today?

One share of EQRX stock can currently be purchased for approximately $1.79.

How much money does EQRx make?

EQRx (NASDAQ:EQRX) has a market capitalization of $872.37 million. The company earns $-169,090,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis.

How many employees does EQRx have?

The company employs 240 workers across the globe.

How can I contact EQRx?

EQRx's mailing address is 667 MADISON AVENUE, NEW YORK NY, 10065. The official website for the company is iii.cmlifesciencesspac.com. The company can be reached via phone at 617-315-2255 or via email at investors@eqrx.com.

This page (NASDAQ:EQRX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -